May.06 -- Gilead Sciences Inc. said it is in talks with leading chemical and pharmaceutical manufacturing companies about the ability to produce remdesivir for Europe, Asia and the developing world through at least 2022 for the treatment of Covid-19. Bloomberg’s Annmarie Hordern reports on “Bloomberg Markets: European Open.”
